Please check your internet connection and try again.
# Ecospirin (Aspirin Enteric-Coated)
## Overview
Ecospirin is an enteric-coated formulation of aspirin, a nonsteroidal anti-inflammatory drug (NSAID) with analgesic, anti-inflammatory, and antipyretic properties. The enteric coating is designed to prevent dissolution in the stomach and release the medication in the small intestine, which may reduce gastric irritation.
## Primary Indications
* **Cardioprotection:** Prevention of myocardial infarction, stroke, and cardiovascular death in patients with a history of cardiovascular disease or at high risk.
* **Analgesia and Anti-inflammation:** Management of mild to moderate pain and inflammatory conditions (though typically other NSAIDs or acetaminophen are preferred for these indications due to the increased gastrointestinal risk with chronic use of aspirin).
## Adult Dosing
* **Cardioprotection:**
* **Primary Prevention:** Generally not recommended due to increased bleeding risk outweighing benefits, especially in those without high cardiovascular risk. If used, low dose: 75-150 mg once daily.
* **Secondary Prevention:**
* Acute Myocardial Infarction (MI): Loading dose of 150-325 mg (non-enteric coated often preferred for rapid absorption), followed by maintenance of 75-150 mg once daily.
* Post-MI, Stroke, or Transient Ischemic Attack (TIA): 75-150 mg once daily.
* **Analgesia/Anti-inflammation:** Doses vary significantly. For mild to moderate pain, 325-650 mg every 4-6 hours as needed. For inflammatory conditions, doses can be higher, up to 4000 mg daily, divided every 4-6 hours. However, due to GI risks and availability of safer alternatives, these higher doses are less common for non-cardioprotective indications. **Always consult specific guidelines for indication.**
## Pediatric Dosing
* **Generally NOT Recommended:** Aspirin is generally **contraindicated** in children and adolescents with viral illnesses (e.g., influenza, chickenpox) due to the risk of Reye's syndrome.
* **Kawasaki Disease:** Specific dosing regimens are used under specialist supervision. Typically, an initial high dose followed by a low maintenance dose. Consult pediatric rheumatology or infectious disease guidelines. Dosing is usually based on weight (e.g., 30-50 mg/kg/day divided into 4 doses for anti-inflammatory effect, followed by 3-5 mg/kg/day once daily for antiplatelet effect).
## Dose Adjustments
* **Renal Impairment:** Use with caution. Dose reduction may be considered in severe renal impairment. Monitor for adverse effects.
* **Hepatic Impairment:** Use with caution. Monitor liver function.
## Contraindications
* Hypersensitivity to aspirin, salicylates, or NSAIDs.
* History of asthma, urticaria, or other allergic-type reactions triggered by aspirin or other NSAIDs.
* Children and adolescents with viral infections (risk of Reye's syndrome).
* Active peptic ulceration or gastrointestinal bleeding.
* Severe hepatic or renal impairment.
* Severe heart failure.
* Bleeding disorders (e.g., hemophilia).
* Third trimester of pregnancy.
## Adverse Effects
* **Gastrointestinal:** Dyspepsia, heartburn, nausea, vomiting, abdominal pain, gastritis, peptic ulceration, GI bleeding (can be severe and life-threatening).
* **Hematologic:** Increased bleeding time, bruising, epistaxis, prolonged bleeding from cuts.
* **Hypersensitivity:** Urticaria, angioedema, bronchospasm, anaphylaxis.
* **Auditory:** Tinnitus, hearing loss (often dose-related).
* **Renal:** Sodium and water retention, renal insufficiency (especially in those with pre-existing renal disease or heart failure).
* **Hepatic:** Elevated liver enzymes.
* **Reye's Syndrome:** In children and adolescents with viral infections.
## Key Drug Interactions
* **Anticoagulants (e.g., warfarin, heparin, DOACs):** Significantly increased risk of bleeding. Concurrent use requires careful consideration and monitoring.
* **Other NSAIDs and COX-2 Inhibitors:** Increased risk of GI toxicity and potential for reduced cardioprotective effect of low-dose aspirin.
* **Corticosteroids:** Increased risk of GI ulceration and bleeding.
* **Antihypertensives (e.g., ACE inhibitors, ARBs, diuretics):** NSAIDs can reduce their efficacy and increase the risk of renal impairment.
* **Methotrexate:** Aspirin can increase methotrexate toxicity.
* **Uricosuric agents (e.g., probenecid):** Aspirin can antagonize the uricosuric effect.
* **Selective Serotonin Reuptake Inhibitors (SSRIs):** May increase the risk of bleeding.
* **Alcohol:** Increased risk of GI irritation and bleeding.
## Monitoring
* **Bleeding:** Monitor for signs and symptoms of GI bleeding (melena, hematemesis, abdominal pain) and other bleeding (bruising, epistaxis).
* **Renal Function:** Especially in patients with risk factors for renal impairment.
* **Hepatic Function:** Periodically, especially with long-term use or higher doses.
* **Gastrointestinal Symptoms:** Assess for dyspepsia or other GI discomfort.
## Clinical Pearls
* The enteric coating delays absorption, making it less suitable for acute pain relief where rapid onset is desired.
* For cardioprotection, low-dose aspirin (75-150 mg) is typically used, and the enteric coating is acceptable. Some guidelines suggest using non-enteric coated aspirin for acute cardiovascular events to ensure faster absorption.
* Patients taking low-dose aspirin for cardioprotection should generally not stop the medication abruptly without consulting their healthcare provider due to increased risk of thrombotic events.
* Inform patients about the increased risk of bleeding and signs/symptoms to report.
* Advise patients to avoid concurrent use of other NSAIDs unless specifically advised by a healthcare provider.
***
**Disclaimer:** This information is intended for healthcare professionals. Always consult the current official prescribing information and relevant clinical guidelines for complete and up-to-date information before making any treatment decisions.
